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Abstract: Platelets are anucleate cells that mediate hemostasis. This occurs via a primary signal that
is reinforced by secreted products such as ADP that bind purinergic receptors (P2Y1 and P2Y12)
on the platelet surface. We recently identified a human subject, whom we termed platelet defect
subject 25 (PDS25) with a platelet functional disorder associated with the P2Y12 receptor. PDS25 has
normal blood cell counts and no history of bleeding diathesis. However, platelets from PDS25 have
virtually no response to 2-MeSADP (a stable analogue of ADP). Genetic analysis of P2Y12 from PDS25
revealed a heterozygous mutation of D121N within the DRY motif. Rap1b activity was reduced in
platelets from PDS25, while VASP phosphorylation was enhanced, suggesting that signaling from the
P2Y12 receptor was interrupted by the heterozygous mutation. To explore this further, we produced
knock-in mice that mimic our subject. Bleeding failed to cease in homozygous KI mice during tail
bleeding assays, while tail bleeding times did not differ between WT and heterozygous KI mice.
Furthermore, occlusions failed to form in most homozygous KI mice following carotid artery injury
via FeCl3 . These data indicate that the aspartic acid residue found in the DRY motif of P2Y12 is
essential for P2Y12 function.
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1. Introduction

Academic Editors: Fadi Khasawneh

The primary physiological function of platelets is to act as an essential mediator in
maintaining homeostasis of the circulatory system by forming hemostatic thrombi that
prevent blood loss and maintain vascular integrity [1,2]. When stimulated with agonists,
platelets change their shape, aggregate, and release their granular contents. Release of
platelet granular contents includes ADP, which binds to purinergic receptors (P2) and is
responsible for potentiation of the initial signal.
Two families of P2 receptors have been described. The P2X receptors are ligand-gated
ion channels, while the P2Y receptors are G protein-coupled receptors (GPCRs) [3]. There
are 8 known P2Y receptors expressed in humans, but only the P2Y1 (Gq ) and P2Y12 (Gi )
receptors are found on platelets [3,4]. ADP binding to P2Y1 is essential for platelet shape
change, while co-stimulation of P2Y1 and P2Y12 is necessary for ADP-induced platelet
aggregation and thromboxane generation [5,6]. We have previously reported that the
P2Y12 receptor also potentiates other agonist-induced platelet functional responses and is
necessary for Akt activation via other agonists [7,8].
P2Y12 is coupled to Gi , which inhibits adenylyl cyclase and results in activation of
phosphoinositide 3-kinase (PI3K) [9]. The activation of PI3K inhibits the RAP-GAP RASA-3
and allows the formation of GTP-bound Rap1b [10]. Activation of Rap1b is important
for integrin activation inside-out signaling, which is essential for hemostasis [11–13]. Not
surprisingly, some mutations within the P2Y12 genome have resulted in bleeding.
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There are several documented examples of human P2Y12 variants which result in different phenotypes from reduced receptor function to a deletion of P2Y12 protein expression.
In several cases the groups responsible for detailing these mutations were able to identify
new amino acid residues that may be important for P2Y12 function. One patient, who
presented with abnormal bleeding, was predicted to have a heterozygous K174E P2Y12
mutation [14]. Platelets from this individual were less sensitive to ADP and it was revealed
that the residue in question is important for receptor interaction with ADP. Another documented P2Y12 missense mutation predicted a P341A substitution, which lies in the PDZ
binding domain. In this case, P2Y12 protein was expressed normally, but resensitization
of the receptor was impaired due to a defect in receptor internalization [15]. Lecchi et al.,
reported on a homozygous mutation found in 2 brothers, which causes impaired receptor
activation [16]. They revealed that H187 is vital for receptor activation as the H187Q mutation found in the 2 brothers permitted ADP to bind P2Y12, but not activate the receptor.
Germane to our study is a report concerning a patient with chronic bleeding that had a
homozygous R122C substitution within the DRY motif of P2Y12 [17]. There are also several
examples of heterozygous and homozygous mutations that result in either reduced or
absent expression of P2Y12 [18–20].
Here, we report on a subject with no bleeding diathesis who is heterozygous for a
D121N substitution within the DRY motif of P2Y12. Platelets isolated from this subject are
refractory to 2-MeSADP stimulation even at high doses but respond to stimulation through
the Gz -coupled epinephrine receptor. An analysis of the coding sequence of P2Y12 revealed
a G to A SNP that predicts a D to N substitution within the P2Y12 receptor.
2. Materials and Methods
2.1. Antibodies and Reagents
All reagents were purchased from Thermo Fisher Scientific unless otherwise stated.
2-MeSADP, ADP, and Apyrase (type V) were purchased from Sigma (St. Louis, MO,
USA). AR-C69931MX was a gift from the Medicines Company (Parsippany, NJ, USA).
AYPGKF was purchased from GenScript (Piscataway, NJ, USA). Phosphorylated Akt S473
and phosphorylated VASP S157 were purchased from Cell Signaling Technologies (Beverly,
MA, USA), while the total Akt antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The total VASP antibody was purchased from Origene (Rockville,
MD, USA). Odyssey blocking buffer and secondary antibodies IRDye 800CW goat antirabbit and IRDye 680LT goat anti-mouse were purchased from Li-Cor (Lincoln, NE, USA).
Collagen and Chronolume, used for the detection of secreted ATP, were purchased from
Chrono-Log Corporation (Havertown, PA, USA). GTP-bound Rap1b was assessed using
a kit from Cell Signaling and cAMP production was measured using a kit from Enzo.
Prostaglandin E1 was also purchased from Enzo (New York, NY, USA). AseI was purchased
from New England BioLabs (Ipswitch, MA, USA).
2.2. Preparation of Human Platelets
Blood was collected from informed, healthy donors into one-sixth volume ACD
(85 mM sodium citrate, 71.4 mM citric acid, and 111 mM dextrose). Human platelets
were prepared as previously described [21]. Platelets were resuspended in Tyrodes
buffer (137 mM sodium chloride, 2.7 mM potassium chloride, 2 mM magnesium chloride, 0.42 mM sodium phosphate monobasic, 10 mM HEPES, 0.1 U/mL Apyrase, and 0.1%
dextrose adjusted to pH 7.4) at a concentration of 2 × 108 /mL. Blood counts were collected
using a Hemavet blood cell analyzer from Drew Scientific (Miami Lakes, FL, USA).
2.3. Platelet Aggregation and ATP Secretion
All platelet aggregation and secretion experiments were carried out using a lumiaggregometer (Chrono-log) at 37 ◦ C under stirring conditions. Platelet aggregation was
measured using light transmission and ATP secretion was measured using Chrono-lume (a
luciferin/luciferase reagent).
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2.4. Western Blotting
Western blotting procedures were performed as described previously [22]. Briefly,
platelets were stimulated for the indicated time points in a lumi-aggregometer with either
a GPVI or a PAR-4 agonist. The reaction was stopped by precipitating the platelet proteins
using 0.6 N HClO4 and washed with water prior to the addition of sample loading buffer.
Platelet protein samples were then boiled for 5 min prior to resolution by SDS-PAGE and
transfer to nitrocellulose membranes. The membranes were then blocked using Odyssey
blocking buffer and incubated overnight with primary antibodies against the indicated
protein. The membranes were then washed with Tris-buffered saline containing 0.1%
tween-20 prior to incubation with appropriate secondary antibodies for 1 h at room temperature. The membranes were washed again and imaged using a Li-Cor Odyssey infrared
imaging system.
2.5. Whole Blood Flow over a Collagen-Coated Surface
Whole blood was obtained from PDS25 and healthy control donors and anticoagulated
using PPACK (Enzo) and Heparin (Sigma). Anticoagulated blood was perfused over a
collagen-coated dish using a chamber from GlycoTech (Gaithersburg, MD, USA) under
arterial (1000 s−1 ) shear rates. A Nikon Eclipse TE300 inverted microscope (200×) was
used to observe thrombus formation and ImageJ (National Institutes of Health) was used
for analysis.
2.6. Animal Housing and Production
Mice were housed in a pathogen-free facility, and P2Y12 D127N mice were produced
by Cyagen Biosciences Inc. (Taicang, China) on a fee for service basis.
2.7. Tail Bleeding Assay
Mouse tail bleeding was conducted as previously described [23]. Mice aged 4–6 weeks
were anesthetized prior to amputation of the distal 3 mm of the tail. The tail was then
immersed in 37 ◦ C saline and bleeding was monitored. If bleeding continued for greater
than 600 s, then bleeding was halted manually by applying pressure.
2.8. Preparation of Mouse Platelets
Mouse blood was collected and platelets were isolated as previously described [22].
The resulting platelets were counted using a Hemavet 950FS blood cell analyzer (Drew
Scientific, Dallas, TX, USA). Platelet counts were adjusted to a final concentration of
1.5 × 108 cells/mL in N-2-hydroxyethylpiperazine-N0 -2-ethanesulfonic acid-buffered
(pH 7.4) Tyrode’s solution containing 0.2 U/mL apyrase.
2.9. Carotid Artery Injury
FeCl3 was used to injure the carotid artery as previously described [23]. Mice aged
10–12 weeks were anesthetized and the carotid artery was exposed. A baseline blood flow
reading was obtained using a Transonic T402 flow meter (Ithaca, NY, USA). The carotid
artery was injured using a 1 × 1 mm piece of filter paper saturated with 7.5% FeCl3 for 90 s.
The filter paper was removed and blood flow was recorded.
2.10. Statistics
All statistical analysis was performed using Microsoft Excel and data was analyzed
using a Student’s t-test where p < 0.05 was considered statistically significant. All data are
presented as means ± STDEV of at least three independent experiments.
3. Results
3.1. ADP-Mediated Platelet Aggregation Is Disrupted in an Otherwise Healthy Human Subject
Platelet Defect Subject 25 (PDS25) is a 29-year-old male who originally enrolled as a
healthy control donor. Blood cell counts from PDS25 were all within normal ranges, he
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Figure 2. VASP phosphorylation is enhanced, while Rap1b-GTP formation is reduced in platelets from
PDS25 stimulated with 2-MeSADP. (A) Representative Western blot showing VASP phosphorylation
in response to either 100 nM 2-MeSADP or 10 mM epinephrine for 3 min with or without PGE1
pretreatment. Total VASP was used to assess loading. (B) Quantitation of VASP phosphorylation
as described in A. (C) Representative Western blot showing Rap1b-GTP in platelets from PDS25
or normal control donors stimulated with 100 nM 2-MeSADP alone or in combination with 10 µM
epinephrine. Rap1b was used to assess loading. (D) Quantitation of GTP-Rap1b expressed as a ratio
of total Rap1b as seen in C. H = Healthy control, P = PDS25. * p < 0.05 vs. control, n = 3.

10 μM epinephrine. Rap1b was used to assess loading. (D) Quantitation of GTP-Rap1b expressed
as a ratio of total Rap1b as seen in C. H = Healthy control, P = PDS25. * p < 0.05 vs. control, n = 3.
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The data presented above suggest that platelets from PDS25 have a defect within the
P2Y12 receptor or downstream signaling. Therefore, we isolated platelets from PDS25 and
healthy control donors and determined whether aggregation via Gz-coupled epinephrine
3.3. Signaling Downstream of Gi-Coupled P2Y12 Is Inhibited in Platelets from PDS25
was intact. Similar to Gi, Gz-mediated signaling results in suppressed cAMP production
The data presented above suggest that platelets from PDS25 have a defect within the
[25]. Epinephrine alone did not cause aggregation in platelets from either control or PDS25
P2Y12 receptor or downstream signaling. Therefore, we isolated platelets from PDS25 and
(Figure
3A). As previously stated, stimulation with 2-MeSADP resulted in aggregation of
healthy control donors and determined whether aggregation via Gz -coupled epinephrine
control
platelets,
buttoonly
shape
change of platelets from PDS25 (Figure 3A). However,
was intact.
Similar
Gi , G
z -mediated signaling results in suppressed cAMP producwhen
2-MeSADP
stimulation
was
with
platelet
tion [25].
Epinephrine
alone did
notsupplemented
cause aggregation
in epinephrine
platelets fromcontrol
either control
oraggregation
while
aggregation
of platelets
from
PDS25
was equivalent
that of conPDS25increased
(Figure 3A).
As previously
stated,
stimulation
with
2-MeSADP
resulted in to
aggregation
of control
platelets, but
only
shape change
of platelets
from PDS25
3A). Howtrol
platelets
stimulated
with
2-MeSADP
alone
(Figure 3A,B).
These(Figure
data suggest
that sigever, when
2-MeSADP
was supplemented
with epinephrine
control platelet
naling
mediated
by Gz stimulation
is intact, while
signaling mediated
by Gi is perturbed
in platelets
aggregation
from
PDS25. increased while aggregation of platelets from PDS25 was equivalent to that of
control platelets stimulated with 2-MeSADP alone (Figure 3A,B). These data suggest that
signaling mediated by Gz is intact, while signaling mediated by Gi is perturbed in platelets
from PDS25.
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5. Thrombus Formation Is Reduced in Whole Blood from PDS25

To determine the consequence of the above observed responses of platelets from PDS25
to various stimuli on thrombus formation, we passed whole blood isolated from PDS25 and
healthy control donors over a collagen coated surface at arterial shear rates. We found that
thrombus formation was significantly inhibited in blood from PDS25 compared to healthy
control blood (Figure 3C,D). These data suggest that thrombus formation is impaired in
PDS25. The data presented above all point to a defect within the P2Y12 receptor. Therefore,
we closely examined the P2Y12 receptor expressed by PDS25.
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3.5. P2Y12 from PDS25 Contains a Novel SNP That Results in a D > N Substitution at
Position 121
We sequenced P2Y12 from PDS25 to determine whether a mutation is present that
may cause the observed phenotype. We amplified the coding sequence of P2Y12 in healthy
donors and PDS25 using the following primers; sense 50 -TTAGAGGAGGCTGTGTCCAA-30
and antisense 50 -GTCGTTTGTTTTGCTGCTAATA-30 with an annealing temperature of
60 ◦ C. We discovered a heterozygous G > A SNP at position 361 of the coding sequence of
P2Y12 that predicts a D > N substitution at position 121 of the protein sequence of P2Y12.
That aspartic acid residue is part of the DRY motif on P2Y12. The DRY motif is highly
conserved among GPCRs and mutations within the DRY motif are known to influence
GPCR function [26–30]. To study the effect of this SNP on in vivo platelet responses we
produced a KI mouse with a similar D > N transition within the DRY motif of P2Y12.
3.6. Reactivity to 2-MeSADP Is Altered in D127N P2Y12 Knock-In Mouse Platelets
Mouse P2Y12 contains additional amino acids so the DRY motif is at position 127
instead of 121 in human. Therefore, we produced D127N knock-in mice via CRISPR/CAS 9.
The nucleotide substitution resulted in an AseI restriction enzyme cut site within the knockin DNA. WT mice contain only the higher base pair product, which is cleaved by AseI
resulting in two lower base pair products (Figure 4A). The heterozygous DNA contains all
three products. P2Y12 D127N KI mice have no gross abnormalities and blood cell counts are
comparable to WT mice (Table 1). Because we introduced a genetic alteration that should
influence the DRY motif of P2Y12 we isolated platelets from WT, heterozygous D127N
(Het), and homozygous D127 knock-in (KI) mice and analyzed aggregation in response
to the P2Y12 (and P2Y1) agonist 2-MeSADP. We found that aggregation in response to
10 nM 2-MeSADP was significantly reduced in platelets from Het mice, but completely
abolished in platelets from homozygous D127N KI mice (Figure 4B,C). When platelets were
stimulated with 100 nM 2-MeSADP aggregation was not different between WT control
and Het mice, but aggregation of D127N KI platelets was significantly reduced compared
to WT (Figure 4D,E). Additionally, we stimulated washed platelets from WT, Het, and KI
mice with the physiological agonist ADP. We found that aggregation was greatly reduced
in KI platelets compared to WT platelets when either 5 µM or 10 µM ADP was used as an
agonist (Figure 5A–C). Further, we stimulated washed platelets isolated from WT, Het, or
KI mice with two concentrations of AYPGKF and measured aggregation and dense granule
secretion. We found that aggregation was unaltered in Het or KI mouse platelets compared
to WT, but dense granule secretion was reduced in KI platelets when a low concentration
of AYPGKF was used (Figure 5D–I). These data are consistent with impaired reactivity to
ADP in the Ki mice.
Table 1. Blood cell counts in WT, Heterozygous D127N, and Homozygous D127N knock-in mice.
Parameter

WT

Heterozygous D127N

Homozygous D127N

WBC (K/mL)
NE (K/mL)
LY (K/mL)
MO (K/mL)
RBC (106 /mL)
Hct (%)
Plt (K/mL)
MPV (fL)

5.67 ± 1.25
0.83 ± 0.23
4.50 ± 1.00
0.44 ± 0.11
9.05 ± 0.20
38.76 ± 0.94
761 ± 29
4.17 ± 0.06

6.04 ± 0.80
0.59 ± 0.08
4.86 ± 0.66
0.59 ± 0.10
9.29 ± 0.25
40.60 ± 1.14
721 ± 33
4.12 ± 0.02

5.06 ± 0.80
0.69 ± 0.09
3.61 ± 0.70
0.54 ± 0.12
9.30 ± 0.48
40.28 ± 1.81
720 ± 56
4.22 ± 0.08
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MO (K/mL)
RBC (106/mL)
Hct (%)
Plt (K/mL)
MPV (fL)

0.44 ± 0.11
9.05 ± 0.20
38.76 ± 0.94
761 ± 29
4.17 ± 0.06

0.59 ± 0.10
9.29 ± 0.25
40.60 ± 1.14
721 ± 33
4.12 ± 0.02

0.54 ± 0.12
9.30 ± 0.48
40.28 ± 1.81
720 ± 56
4.22 ± 0.08
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3.7. Hemostasis and Thrombosis Are both Interrupted in P2Y12 D127N Knock-In Mice
and secretion (H) from WT, Het, and KI platelets stimulated with 500 µM AYPGKF.

To determine whether hemostasis is altered by the D127N transition we performed
tail bleeding experiments in WT, Het, and homozygous KI mice. We found that there was
no difference in tail bleeding times between WT and Het (Figure 6A). However, tail bleeding had to be stopped mechanically in all KI mice. Therefore, an intact DRY motif within
P2Y12 is crucial for the maintenance of hemostasis. To determine the effect of a disrupted
DRY motif in P2Y12 on thrombosis we injured the carotid artery of WT, Het, and homozygous KI mice with 7.5% FeCl3 for 90 s and monitored blood flow. Time to occlusion was
significantly enhanced in Het mice compared to WT control mice, suggesting that even a
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To determine whether hemostasis is altered by the D127N transition we performed tail
bleeding experiments in WT, Het, and homozygous KI mice. We found that there was no
difference in tail bleeding times between WT and Het (Figure 6A). However, tail bleeding
had to be stopped mechanically in all KI mice. Therefore, an intact DRY motif within P2Y12
is crucial for the maintenance of hemostasis. To determine the effect of a disrupted DRY
motif in P2Y12 on thrombosis we injured the carotid artery of WT, Het, and homozygous KI
mice with 7.5% FeCl3 for 90 s and monitored blood flow. Time to occlusion was significantly
enhanced in Het mice compared to WT control mice, suggesting that even a partial loss of
WT P2Y12 can have an impact on thrombus formation (Figure 6B,C,E). Consistently, the
carotid artery in all but 2 KI mice failed to occlude over the 30 min experiment (Figure 6D,E).
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tory of bleeding. Further, platelets from the R122C subject did not aggregate in response
to ADP, which is similar to the phenotype observed when platelets from PDS25 are stimulated with 2-MeSADP. It is interesting that platelets from two family members of the
R122C subject were also tested and both had at least mild aggregatory responses to low
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which is similar to the phenotype observed when platelets from PDS25 are stimulated with
2-MeSADP. It is interesting that platelets from two family members of the R122C subject
were also tested and both had at least mild aggregatory responses to low dose ADP. Both
family members were heterozygous. This suggests that the aspartic acid and the arginine
within the DRY have separate functions, as PDS25 had no aggregatory response to high
dose 2-MeSADP.
The primary reason for generating a knock-in mouse model of D127N P2Y12 is to
determine whether the mutation affects thrombosis or hemostasis or both. It is well known
that P2Y12 antagonism protects patients from thrombosis but may result in bleeding. Therefore, we expected to see a loss of hemostasis and interrupted thrombosis in homozygous
D127N knock-in mice, which is what we observed. We were more interested in the phenotype of the heterozygous mice because our subject is heterozygous for the mutation.
Furthermore, our subject has not experienced excess bleeding. Indeed, tail bleeding, a
measure of hemostasis, was not altered in heterozygous D127N mice. However, occlusion
following FeCl3 -induced injury was prolonged and thrombus stability was reduced in
heterozygous D127N mice compared to WT control mice. This is notable because bleeding
is often associated with P2Y12 antagonism and because the isolated platelet phenotype
resulting from the D121N mutation in our subject is severe. That said, we were surprised
by the reactivity of platelets isolated from heterozygous D127N mice.
Isolated platelets from the heterozygous D127N mouse do not phenocopy platelets
isolated from PDS25. While we were unable to measure any appreciable aggregation of
platelets from PDS25 when stimulated with 100 nM 2-MeSADP, we were able to measure
aggregation in heterozygous knock-in mice at 10 nM 2-MeSADP and aggregation resulting
from 100 nM 2-MeSADP was not different from WT control. We believe the explanation for
this discrepancy may be linked to the copy number of P2Y12 on mouse and human platelets.
A report in 2013 suggests that humans have 425 ± 50 copies of P2Y12 on the platelet surface,
while mouse platelets contain 634 ± 87 copies of P2Y12 [34]. The approximate 50% increase
in P2Y12 copy number in mouse is magnified by the small size of the mouse platelet. In
PDS25 we were able to observe an increase in pAkt S473 following 2-MeSADP stimulation,
and this was abolished with AR-C69931MX pretreament suggesting that there is some
signaling originating from P2Y12 in platelets from PDS25. It is possible that there are
not enough WT copies of P2Y12 available to induce aggregation of platelets from PDS25,
but there are enough WT copies over a smaller surface area of platelets from D127N
heterozygous platelets. It is not yet clear whether oligomerization, heterodimerization, or
G-protein coupling is the reason for the lack of aggregation in PDS25, but that would be an
interesting area of exploration.
Others have mutated the DRY motif in other GPCRs. In most cases the mutated
GPCR becomes constitutively active [28,29,35–38]. There are, however, those that develop
constitutive inactivity [27,39,40]. We appear to have the latter phenotype with PDS25,
but that is not necessarily the case. The aspartic acid in the DRY motif is thought to
regulate receptor conformation, the mutation of which may allow the receptor to adopt
an active conformation. Interestingly, this active conformation does not always equate
to constitutive activity. For instance, in the TP receptor an E129V (DRY can also be ERY)
mutation resulted in greatly enhanced agonist binding, but the mutation is classified as
constitutively inactive [27]. The same can be said of other similar mutations in some other
GPCRs [39,41,42]. Therefore, at this time, it is unclear which category D121N would fit.
Here, we show a novel P2Y12 variant that results in a D < N transition within the
DRY motif. Given that PDS25 has never had a bleeding complication of any sort, and that
inhibition of P2Y12-mediated platelet aggregation is greater than one would see in platelets
isolated from a patient treated with a commercial P2Y12 antagonist, we believe there is a
tremendous opportunity here for discovery.
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